Gilead gives Remdesivir to support Ethiopia’s Marburg virus response

Gilead Sciences is a leading life sciences company dedicated to advancing breakthroughs in various therapeutic areas, including virology, HIV, viral hepatitis, neglected and emerging viruses, pandemic preparedness, oncology, and inflammation. With a focus on research and development, Gilead is committed to finding innovative solutions to address unmet medical needs.

In the realm of research, Gilead offers funding programs such as the Research Scholars Program and External-Sponsored Research to support studies in virology, oncology, and inflammation. The company also provides opportunities for community-based participatory research and publishes its research findings in various publications. Clinical trials play a crucial role in testing new medicines and ensuring patient safety, with Gilead placing a strong emphasis on diversity in clinical trials.

When it comes to medicines, Gilead places a high priority on patient safety, anti-counterfeiting efforts, and consumer product safety. The company encourages individuals to report any adverse events related to its medications and strives to ensure access to its products for patients in need through various access programs and partnerships with authorized distributors.

Responsibility is a core value at Gilead, with a focus on environmental, social, and governance (ESG) performance. The company has outlined specific ESG focus areas, frameworks, and reporting mechanisms to drive sustainability initiatives. Health equity is a key priority area for Gilead, and the company actively engages in corporate giving through strategic initiatives like All4Liver, COMPASS Initiative, HepConnect, and many others aimed at supporting communities and improving health outcomes.

Gilead’s commitment to health equity extends globally, with initiatives in Africa, Asia, Australia, Europe, the Middle East, Latin America, and North America. The Gilead Foundation plays a vital role in supporting these efforts through programs like the Creating Possible Fund and building community donations. Global health and access initiatives focus on improving access to healthcare in low- and middle-income countries, with a specific focus on long-acting pre-exposure prophylaxis (PrEP) and invasive fungal infections.

Inclusion and diversity are top priorities at Gilead, with various employee resource groups like ADAPT, GAIN, Gileados, GLOBE, GVET, Pride Alliance, and Women at Gilead fostering a culture of diversity and inclusion within the company. Medical education plays a crucial role in advancing healthcare practices, and Gilead is dedicated to sharing stories of impact and innovation across the medical community.

Gilead’s leadership team, board of directors, and governance structure reflect the company’s commitment to excellence, with individuals like Daniel O’Day, Andrew Dickinson, Stacey Ma, and others leading the way in driving innovation and growth. The company’s dedication to ethical practices, compliance, and transparency is evident in its policies and procedures, ensuring that all stakeholders are informed and engaged in Gilead’s mission to create a healthier world.